Antivirals and resistance: influenza virus

被引：158

作者：

Ison, Michael G. ^{[1
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA

来源：

CURRENT OPINION IN VIROLOGY | 2011年 / 1卷 / 06期

关键词：

SIALIDASE FUSION PROTEIN; CRITICALLY-ILL PATIENTS; ACTING NEURAMINIDASE INHIBITOR; A H1N1; INTRAVENOUS ZANAMIVIR; HOSPITALIZED-PATIENTS; OSELTAMIVIR RESISTANCE; TRANSPLANT RECIPIENTS; ADAMANTANE RESISTANCE; RESPIRATORY-FAILURE;

D O I：

10.1016/j.coviro.2011.09.002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Influenza causes annual epidemics of respiratory viral infections are associated with significant morbidity and mortality. Influenza vaccines have been shown to reduce the risk of infection and mitigate against some of the virus' sequellae. Likewise, two classes of antivirals, the adamantanes (amantadine and rimantadine) and the neuraminidase inhibitors (laninamivir, oseltamivir, peramivir, and zanamivir) are currently approved for the prevention and treatment of influenza; several other classes of antivirals and immune modulators are also currently under investigation. One of the greatest challenges to our armamentarium of antivirals is the emergence of resistant mutants. In this paper, we will review the currently approved and investigational antiviral agents and the mechanisms of resistance that impact their activity.

引用

页码：563 / 573

页数：11

共 111 条

[11] Drugs in Development for Influenza [J].

Boltz, David A. ;

Aldridge, Jerry R., Jr. ;

Webster, Robert G. ;

Govorkova, Elena A. .

DRUGS, 2010, 70 (11) :1349-1362

[12]

Borroso L, 2005, ANTIVIR THER, V10, P901

[13] Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States [J].

Bright, RA ;

Shay, DK ;

Shu, B ;

Cox, NJ ;

Klimov, AI .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (08) :891-894

[14] Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern [J].

Bright, RA ;

Medina, MJ ;

Xu, XY ;

Perez-Oronoz, G ;

Wallis, TR ;

Davis, XHM ;

Povinelli, L ;

Cox, NJ ;

Klimov, AI .

LANCET, 2005, 366 (9492) :1175-1181

[15] Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness [J].

Brookes, Daniel W. ;

Miah, Shahajahan ;

Lackenby, Angie ;

Hartgroves, Lorian ;

Barclay, Wendy S. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (03) :466-470

[16] Surfactant Therapy and Intravenous Zanamivir in Severe Respiratory Failure Due to Persistent Influenza A/H1N1 2009 Virus Infection [J].

Busani, Stefano ;

Girardis, Massimo ;

Biagioni, Emanuela ;

Pasetto, Alberto ;

Sambri, Vittorio .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (10) :1334-1334

[17] Respiratory Failure Caused by 2009 Novel Influenza A/H1N1 in a Hematopoietic Stem-Cell Transplant Recipient: Detection of Extrapulmonary H1N1 RNA and Use of Intravenous Peramivir [J].

Campbell, Angela P. ;

Jacob, Shevin T. ;

Kuypers, Jane ;

Wald, Anna ;

Englund, Janet A. ;

Corey, Lawrence ;

Boeckh, Michael .

ANNALS OF INTERNAL MEDICINE, 2010, 152 (09) :619-620

[18] Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers [J].

Cass, LMR ;

Efthymiopoulos, C ;

Bye, A .

CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :1-11

[19]

Cervantes-Gonzalez M, 2010, EXPERT REV ANTI-INFE, V8, P981, DOI [10.1586/eri.10.83, 10.1586/ERI.10.83]

[20] STRUCTURE OF THE CATALYTIC AND ANTIGENIC SITES IN INFLUENZA-VIRUS NEURAMINIDASE [J].

COLMAN, PM ;

VARGHESE, JN ;

LAVER, WG .

NATURE, 1983, 303 (5912) :41-44

← 1 2 3 4 5 6 7 8 9 10 →